Fig. 5: Clinical utility of deleterious missplicing mutations.

A The distributions of mutations per gene for the sets of all genes analyzed, canonical cancer drivers, and the proposed cancer genes show that the proposed genes come from the same distribution as the background gene set rather than having been selected based on trivial characteristics such as mutation volume. B While the mutation volume for the proposed cancer drivers is not significantly different from all genes analyzed, the pathogenicity of the mutations found in these genes is significantly higher. C Kaplan–Meier survival probabilities for groups of patients defined using mutations within proposed cancer genes. D Kaplan–Meier survival probabilities for groups of patients defined using mutations within canonical cancer genes. E Kaplan–Meier survival probabilities for two groups of patients with similar mutation volumes segmented based on having or not having deleterious mutations. F Distribution of mutation volumes for patients in groups identified in E shows that the patients do not have significantly different numbers of mutations.